A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow up, Single Dose-escalation Study of VTX-801 in Adult Patients with Wilson’s Disease.
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Vivet Therapeutics, SAS
This Clinical Trial is being conducted to assess the effects of an experimental drug (study drug) called VTX-801 intended to treat Wilson’s Disease (WD). The purpose of this clinical study is to assess what effects, good and bad, VTX-801 may have on you and your WD and to find the most appropriate dose for future clinical trial(s).